I
nsulin-secreting islet ␤-cells play a pivotal role in the regulation of fuel metabolism. Loss or dysfunction of ␤-cells causes an imbalance in glucose homeostasis that leads to the development of diabetes. Efforts aimed at understanding the molecular processes underlying ␤-cell development and function have provided perspectives into new diabetes treatment strategies. For example, a hierarchy of transcription factors has been found to regulate ␤-cell differentiation during development and adult islet cell function, a few of which are mutated in type 2 diabetic patients as discussed by others (1) (2) (3) . The significance of these proteins was recently reinforced upon observing their expression during the stepwise differentiation of human embryonic stem cells to ␤-like cells (4, 5) and the reprogramming of adult acinar cells to ␤-like cells upon misexpression of a unique subset of transcription factors, specifically MafA, Pdx1, and Ngn3 (6) .
Among the transcription factors vital to the pancreas, there are instances when members of the same gene family contribute to ␤-cell formation, including wingedhelix/forkhead (e.g., FoxA1/2) (7-9), NK6 homeodomain (Nkx6.1 and Nkx6.2) (10 -12), paired box homeodomain (Pax4/6) (13) (14) (15) (16) (17) , and basic leucine-zipper (MafA and MafB) (18, 19) proteins. FoxA1/2, Nkx6.1/6.2, and Pax4/6 are expressed broadly in pancreatic epithelial cells in both islet hormone ϩ and hormone Ϫ cells before or near the onset of pancreatic morphogenesis (3) and then become confined to more specific cellular domains (e.g., Nkx6.1 [␤] and Pax6 [all islet cells]) or disappear entirely late in development (Pax4, Nkx6.2). The large MafA/B factors are distinct in being produced relatively later in development and essentially only in hormone ϩ cells. Thus, MafB is present in developing ␣-(glucagon ϩ ) cells, ␤-cells, and a very small number of Ngn3 ϩ islet hormone Ϫ progenitors and then becomes restricted to ␣-cells soon after birth (20, 21) . MafA is found exclusively in developing and adult insulin ϩ cells, with expression first detected at embryonic day (E) 13.5 during the secondary and principal wave of insulin ϩ cell production (22) . A comparison of the properties of islet-enriched transcription factor mutant mice reveals a novel role for MafA and MafB in ␤-cell maturation and function. Thus, islet ␣, ␤, ␦, ε, or pancreatic polypeptide producing cells are either lost or respecified in most transcription factor knockout mice (1) (2) (3) , whereas the principal defect in MafB Ϫ/Ϫ embryos is reduced insulin and glucagon expression (18) . Furthermore, this change does not affect total endocrine cell numbers, supporting a distinct importance in one or more late steps in ␣-and ␤-cell differentiation (18) . In contrast, MafA is solely required for glucose-regulated insulin secretion in adult islet ␤-cells and is not involved in islet cell development (19) . Notably, MafB ϩ insulin ϩ cells generated during human embryonic stem cell differentiation were dysfunctional until becoming MafA ϩ insulin ϩ (5), suggesting that the transition from MafB to MafA is critical to ␤-cell function.
To obtain a mechanistic understanding of the association between MafB and MafA in ␤-cell formation and function, gene-profiling studies were performed with E18. (18, 21) . Significantly, MafB-dependent genes were associated with adult ␤-cell function, including glucose sensing and insulin secretion. Interestingly, many of these target genes were affected in a similar manner in adult MafA ⌬Panc islets, even though MafB was retained in a fraction of the mutant insulin ϩ cell population. These findings provide insight into why the ␤-cell is dysfunctional in MafA mutant mice, and they illustrate the unusual interrelationship between closely related transcription factors in the generation of a particular islet cell type.
RESEARCH DESIGN AND METHODS
Animals. Pancreas-wide MafA deletion mutant mice were generated using the Cre-loxP mediated recombination system. A conditional MafA allele was generated using a targeting vector consisting of two loxP sites inserted into the 5Ј (PstI site [Ϫ699 bp] and 3Ј (KpnI site [1,658 bp (Qiagen) , and RNA quality was analyzed using an Agilent 2100 Bioanalyzer. Each RNA sample (100 ng) was amplified using the Ovation Aminoallyl RNA Amplification and Labeling System (NuGEN Technologies), and PancChip 6.1 (http://www. betacell.org/ma, supplementary reference 2) microarray analysis was performed at the Functional Genomics Core at the University of Pennsylvania.
Quantitative RT-PCR was conducted on total RNA from E18.5 pancreata or 12-week-old islets (n Ն 3 for each genotype). The RNA (1 g) was transcribed using iScript reverse transcriptase and iScript reaction mix (Bio-Rad). The PCRs were performed using the SYBR Green (with dissociation curve) program on an Applied Biosystems 7900 machine. All reactions were performed in duplicate with reference dye normalization, and median cycling threshold values were used for analysis. Primer sequences are available on request. Immunohistochemistry and in situ hybridization. Tissue fixation, embedding, and immunofluorescence labeling were performed as previously described (25) . The primary antibodies used were guinea pig ␣-insulin (1:2,000; Linco Research), mouse ␣-insulin (1:2,000; Invitrogen), guinea pig ␣-glucagon (1:2,000; Linco Research), sheep ␣-somatostatin (1:2,000; American Research), guinea pig ␣-pancreatic polypeptide (1:2,000; Linco Research), rabbit ␣-MafB (1:10,000; Bethyl Laboratories), rabbit ␣-MafA (1:1,000, Bethyl Laboratories), rabbit ␣-Slc30a8 (1:1,000, Mellitech), mouse ␣-Rbp4 (1:1,000, Abnova), rabbit ␣-G6PC2 (1:500, a gift from Dr. John Hutton at the University of Colorado), rabbit ␣-Pdx1 (1:5,000, a gift from Dr. Chris Wright at Vanderbilt University), mouse ␣-Isl1 (1:300, Developmental Studies Hybridoma Bank), rabbit ␣-Nkx6.1 (1:1,000, Beta Cell Biology Consortium), and rabbit ␣-Pax6 (1:200, Covance Research Products). The secondary Cy2-, Cy3-, or Cy5-conjugated donkey ␣-rabbit, ␣-guinea pig, and ␣-sheep IgGs were obtained from Jackson ImmunoResearch Laboratories. Nuclear counterstaining was performed using YoPro1 or DAPI (Invitrogen). Immunofluorescence images were acquired using confocal microscopy (LSM510, Carl Zeiss).
In situ hybridization assays were performed using Neuronatin (base pair 119 to 1,163 relative to coding ATG) and Slc30a8 (base pair 166 to 1,269) gene probes according to Henrique et al. (26) . The Rbp4 cDNA plasmid (clone ID IMAGp998P0711141Q1) was obtained from the resource center of the human genome project (www.rzpd.de) and used to generate the probe (base pair 295-927). Quantification and statistical analysis. Immunolabeling for insulin and MafA (or MafB) was performed on serial 6-m pancreatic sections that were collected at 60-m (i.e., at E14.5), 84-m (E18.5), or 150-m (postnatal) intervals. All insulin ϩ cells were imaged by confocal microscopy and presented as the percentage of MafA ϩ insulin ϩ or MafB ϩ insulin ϩ to total insulin ϩ cells. At least 10 random fields were counted from wild-type and MafA ⌬Panc pancreata (n ϭ 3) to calculate the percentage of MafB ϩ insulin ϩ cells in adult islets. Immunolabeling for insulin, glucagon, somatostatin, and pancreatic polypeptide-producing cells was performed on 12-week islet sections at 300-m intervals. At least 10 random fields were counted from wild-type and MafA ⌬Panc pancreata (n ϭ 4) to calculate the proportion of somatostatin ϩ ␦-cells within islets. Mean differences were tested for statistical significance using a two-tailed Student t test.
RESULTS
MafA and MafB are dynamically expressed in developing and adult ␤-cells. There are two distinct waves of insulin ϩ and glucagon ϩ cell production within the pancreatic epithelium during embryogenesis, with the massive expansion of secondary transition cells starting at E13.5 populating the adult islet (27) . Previous studies established that MafB is expressed in both waves (18, 21) , whereas MafA is only in the insulin ϩ cells of the second wave (22) . Quantitative immunohistochemical analysis was performed at E15.5, E18.5, P14, and P28 to precisely define the MafA and MafB expression pattern during embryonic and postnatal ␤-cell differentiation.
MafB was found in almost all insulin ϩ cells produced at E14.5 and E18.5, whereas the fraction of MafA ϩ insulin ϩ cells increased during this period (Fig. 1A) . Our results are in accordance with previous data showing that MafA was expressed in only 54% of the insulin ϩ cells at E15.5 and MafB in nearly 90% (21) . However, MafB was present only in very few insulin ϩ cells soon after birth (P14, 2.70 Ϯ 0.11%) and was essentially absent in insulin ϩ cells after 4 weeks (P28, 0.69 Ϯ 0.06%). In contrast, MafA was detected in most islet ␤-cells by 4 weeks (Fig. 1A) . The postnatal switch in ␤-cells from principally MafB to exclusively MafA occurs during a period of cell maturation in regards to islet architecture, islet cell mass, and glucose-sensitive insulin secretion. Table 1 ). In contrast, no differences were found between MafA ⌬Panc and the wild-type gene expression profile.
Gene ontology analysis revealed that the differentially expressed genes were mainly involved in aspects of mature ␤-cell function, such as ion binding and transport, signal transduction, and hormone secretion (supplementary Table 2 (Table 1 ; data not shown). The studies described below examined the significance of MafA in adult expression of genes initially regulated by MafB. Expression within specific islet cell types was examined by in situ hybridization during development and by immunohistochemistry in adults; unfortunately, limitations in the technique (e.g., in situ) or protein abundance precluded examination of these temporal periods using both methods. Importantly, our results provide mechanistic insight into the mutually beneficial relationship between MafB and MafA and provide an explanation for why ␤-cell activity decreases in MafA Ϫ/Ϫ and MafA ⌬Panc mice. MafB activates Slc30a8-encoded zinc transporter expression in developing ␣-and ␤-cells, whereas MafA is essential in adult ␤-cells. Slc30a8 or ZnT8 encodes an islet-specific zinc transporter that facilitates the accumulation of zinc from the cytoplasm into intracellular vesicles for insulin maturation and storage (28, 29) . Overexpression of Slc30a8 enhances glucose-stimulated insulin secretion in INS1 ␤-cells (29), whereas variants in this locus are linked to type 2 diabetes in humans (30, 31) . The transporter is also a type 1 diabetes autoantigen in humans (32) .
The normal Slc30a8 expression pattern during pancreatic development was first determined by in situ hybridization. Slc30a8 mRNA transcripts were found in both developing ␤-and ␣-cells ( Fig. 2A-D, supplementary Fig. 3) . Notably, Slc30a8 expression was lost in ␣-cells at E18.5 in the MafB Ϫ/Ϫ mutant, but retained in the remaining insulin ϩ cells (Fig. 2E and F, supplementary  Fig. 3) . Significantly, Slc30a8 expression was undetectable in the MafA ⌬Panc ;MafB Ϫ/Ϫ mutant ( Fig. 2G and H,  supplementary Fig. 3 ), demonstrating that expression was mediated by MafA in the residual insulin ϩ cells in the MafB mutants. These results suggest that MafB is the primary activator of Slc30a8 expression in ␣-and ␤-cells during development.
Next, immunohistochemical staining was performed to assess Slc30a8 expression in adult wild-type and MafA ⌬Panc islets. As reported while this work was in progress (33), Slc30a8 is present in both ␣-and ␤-cells ( Fig. 2J and K) . (The specificity of the Slc30a8 antibody was confirmed upon comparing pancreatic samples from wild-type and Slc30a8 Ϫ/Ϫ mice [supplementary Fig. 4] ). Expression was essentially absent in 3-month-old islet insulin ϩ cells from the MafA ⌬Panc mutant (Fig. 2L) . The remaining Slc30a8 in MafA ⌬Panc islets is primarily (if not exclusively) in ␣-cells (Fig. 2M) . These data imply that MafA and MafB function at distinct temporal stages to promote Slc30a8 expression in ␤-cells. Both MafA and MafB activate islet-specific glucose-6-phosphatase catalytic subunit-2 protein expression. Glucose-6-phosphatase catalytic subunit-2 protein (G6pc2, also known as IGRP) is a major autoantigen in type 1 diabetes (34) and may regulate fasting plasma glucose levels in humans (35) . Expression of G6pc2 mRNA was significantly compromised in E18.5 pancreata from MafB Ϫ/Ϫ , MafA ⌬Panc ;MafB Ϫ/Ϫ , and MafA ⌬Panc embryos. However, the impact of MafA appears greater in adult MafA ⌬Panc islets than during development (see Fig. 3A and Table 1 ), as a much lower level of G6pc2 was present in 3-month-old MafA ⌬Panc islet ␤-cells than wild-type (Fig. 3 , compare D with G). These data indicate that both MafA and MafB play a role in G6pc2 expression and complement recent cell-line-based studies showing that MafA stimulates G6pc2 transcription by binding to the Ϫ177/Ϫ164 bp element in its promoter region (36) . Neuronatin expression is principally regulated by MafB. Neuronatin (Nnat) is involved in modulating ion channel activity in ␤-cells, with overexpression increasing insulin secretion by elevating intracellular Ca 2ϩ levels (37, 38) . In situ hybridization analysis showed that Nnat mRNA was expressed at E15.5 and E18.5 in insulin ϩ cells and in a population that was neither insulin ϩ nor glucagon ϩ (Fig. 4 (Fig. 4 , supplementary Figs. 5 and 6).
These results suggest that Nnat expression in developing ␤-cells is only partially dependent on MafB. This was also true of Pdx1 transcription wherein the ϳ50% reduction in E18.5 mRNA levels reflected the loss in the MafB Ϫ/Ϫ insulin Ϫ cell population (18) . Notably, steadystate Nnat (Fig. 4M) and Pdx1 (19) levels were unchanged in MafA ⌬Panc adult islets, a distinction from Slc30a8 (Fig.  2I) or G6pc2 (Fig. 3A ). These data demonstrate that only MafB regulates Nnat expression. Rbp4 expression is upregulated in E18.5 MafB mutant and MafA ⌬Panc adult islets. Rbp4 contributes to the pathogenesis of type 2 diabetes, as its release from adipocytes causes systemic insulin resistance in both mice and humans (39) . This circulating protein is also produced in the liver, although little was known about its effect on islets until recently. Rbp4 has now been found to repress glucose-stimulated insulin secretion in both isolated rat islets and in vivo (P. Fueger, C. Newgard, unpublished data).
In distinction to the genes described previously, Rbp4 mRNA expression was increased in MafB Ϫ/Ϫ and MafA ⌬Panc ;MafB Ϫ/Ϫ pancreata at E18.5 (Table 1) . In situ RNA analysis was performed to determine the distribution of Rbp4 in hormone ϩ cells during development. Rbp4 transcripts were found in the majority of wild-type insu- Quantitative RNA analysis demonstrated that adult MafA ⌬Panc islets contained elevated Rbp4 mRNA levels (Fig.  5P) . Notably, Rbp4 protein expression was detected only in somatostatin-producing ␦-cells in both wild-type and
MafA
⌬Panc islets (Fig. 5Q-X) . However, there was no change from the wild-type in the somatostatin ϩ ␦-cell proportion produced in mutant islets (wild-type: 8.94 Ϯ 0.73% vs. MafA ⌬Panc : 8.59 Ϯ 0.89%). Collectively, the data indicate that MafA and MafB negatively regulate production of this effector of insulin secretion and insulin resistance in developing and mature islet cell types. islet transcriptional regulators. Hence, the MafA Ϫ/Ϫ mutant affects only adult islet architecture and ␤-cell activity, whereas MafB and essentially all other pancreatic transcriptional regulators (at least) affect islet cell development. Here we have examined the relationship between these closely related factors in islet ␤-cell formation and function, an especially important issue considering that MafB is not produced within this islet cell population in adults.
Histologic and gene expression analyses of regulated genes identified from a microarray screen performed on E18. levels, or more interestingly, because of differences in activation properties with MafA. In this regard, it is noteworthy that MafA was found to activate Insulin expression, whereas MafB specifically stimulated glucagon in experiments performed in endocrine cells (20, 22, 40) .
Expression profiling analysis showed that MafB activates genes involved in mature endocrine function, including those significant to glucose sensing (e.g., Slc2a2), vesicle maturation (Slc30a8), Ca 2ϩ signaling (Camk2b), and insulin secretion (Nnat) ( Table 1, supplementary  Table 2 ; data not shown). In contrast, the levels of transcription factors associated with ␤-cell differentiation (e.g., Pax6, NeuroD1, Pax4, and Isl1) were unaffected in the MafB Ϫ/Ϫ (or MafA
) mutant, supporting a role for MafB in late events essential to cell maturation and not early islet cell specification (e.g., Ngn3) or cell lineage commitment steps (e.g., Arx, Isl1, Nkx2.2, Pax4, and Pax6) (18) . This proposal is also supported by the fact that MafB Ϫ/Ϫ mutant retained the expression of some ␣-and ␤-cell-enriched developmental markers while undergoing a loss in insulin and glucagon production (18 (Fig. 2 ). Instances were also found when MafB was the primary (if not exclusive) activator, such as Nnat (Fig. 3) and Pdx1 (data not shown).
Given the significance of MafA and MafB mutual target genes (e.g., Slc30a8, Insulin, and Slc2a2) to ␤-cell function, insulin secretion defects associated with the MafA Ϫ/Ϫ (19) and MafA ⌬Panc mutants would be expected. The recent studies showing that Rbp4 produced from rat islet cells inhibits glucose-stimulated insulin secretion (P. Fueger, C. Newgard, unpublished data) suggests that activation in ␦-cells of MafA ⌬Panc mouse would also act to diminish ␤-cell function. (Rbp4 is also principally expressed in human islet ␦-cells [supplementary Fig. 9] ). Rbp4 attenuates insulin-induced phosphorylation of insulin receptor substrate-1 in human adipocytes (supplementary reference 3). Presumably, it also inhibits insulinresponsive signalling that is essential to ␤-cell function (supplementary reference 4). We believe that the increased Rbp4 expression in ␦-cells is a byproduct of MafA ⌬Panc ␤-cell inactivity. Further investigation may reveal that islet Rbp4 expression is also induced in mouse models of type 2 diabetes wherein islet MafA expression was selectively lost (43, 44) .
Although other closely related transcription factors are synthesized within the pancreas (e.g., Pax4/Pax6, Nkx6.1/ Nkx6.2, FoxA1/FoxA2), none act as specifically and in such a coordinated manner to affect islet cell function as MafA and MafB. For instance, Nkx6.1 and Nkx6.2 are expressed more broadly and earlier, with only Nkx6.1 significantly influencing ␤-cell development and function (10, 12, 45) . Likewise, FoxA1 and FoxA2 have a similar early expression pattern to Nkx6.1/6.2 in the forming pancreas, with the dominant and general role in islet cell formation and function served by FoxA2 (7) (8) (9) . Perhaps parallels can be made between islet MafA and MafB and the basic helix-loop-helix Myf-5, MyoD, and Myogenin factors through their actions in skeletal muscle formation. Hence, gene knockout experiments in mice have shown that myogenin plays an essential role in the late differentiation of myoblasts to myotubes (46) (analogous to MafA in the maturing ␤-cell), whereas both Myf-5 and MyoD act upstream and are critical to myoblast formation (47) (acting similarly to MafB). However, expression of any of these myogenic factors can convert a variety of tissue culture cells into muscle cells (48, 49) , whereas only MafA appears capable of activating Insulin transcription in vitro (22, 40) . Interestingly, differences in myogenic potential was revealed when Myogenin was expressed from the Myf5 locus in vivo (48) , suggesting that a knock-in analysis might also reveal elementary regulatory differences between the MafA and MafB proteins.
